All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Breast cancer is now the leading cause of cancer death among women in economically developing countries. This statistic represents a shift from the previous decade, during which the most common cause of death from cancer was cervical cancer\[[@pone.0125655.ref001]\]. There are approximately 13 million new cases of breast cancer worldwide each year\[[@pone.0125655.ref002]\]. Mastectomy is the primary treatment for breast cancer; however, it damages a patient's body image and has adverse effects on emotions, psychology, and social life\[[@pone.0125655.ref003]\].

To correct these problems, breast reconstruction has become increasingly popular. Patients who have undergone mastectomy have two options for breast reconstruction: immediate breast reconstruction (IBR) and delayed breast reconstruction (DBR). IBR is advantageous over DBR because it decreases the total number surgical procedures and the risks therein. Additional advantages include psychological benefits, reduced recovery time, improvements in the quality of life, and lower costs\[[@pone.0125655.ref004]--[@pone.0125655.ref006]\]. Some factors, such as age, socio-economic status, and tumor stages, can influence whether patients will receive IBR following mastectomy. These factors also influence the prognosis of the disease\[[@pone.0125655.ref007]\].

Because IBR is an additional surgical procedure, it may increase postoperative complications (such as flap necrosis, infection, hematoma)\[[@pone.0125655.ref008],[@pone.0125655.ref009]\] and delay the initial time to adjuvant chemotherapy in some patients\[[@pone.0125655.ref010],[@pone.0125655.ref011]\]. Adjuvant chemotherapy, an important component of systemic therapy for patients with breast cancer, decreases disease recurrence and improves survival. Johnson et al reported that large intervals between surgery and initial chemotherapy can be harmful\[[@pone.0125655.ref012]\]. Lohrisch et al found no significant differences in recurrence-free survival (RFS) and overall survival (OS) among women who started chemotherapy up to 12 weeks after surgery (groups analyzed: ≤ 4 weeks, \> 4 weeks to 8 weeks, \> 8 weeks to 12 weeks), but the 5-year OS and RFS of women who started chemotherapy more than 12 weeks after surgery were lower than those of women who started earlier (*P* \< 0.05)\[[@pone.0125655.ref013]\]. These findings suggest that the prognosis of breast cancer may be compromised by delaying chemotherapy for more than 12 weeks after definitive surgery, as might be the case for patients who undergo IBR. Therefore, we systemically reviewed relative data to investigate the impact of IBR on the prognosis of breast cancer.

Methods {#sec006}
=======

Search strategy and selection criteria {#sec007}
--------------------------------------

The Medline (Pubmed), ISI Web of Knowledge, Embase, and Google Scholar databases were searched by entering the following terms: "immediate breast reconstruction," "recurrence," "survival," "safety," and "prognosis." The search was limited to the English language only. The inclusion criteria were as follows: (1) the study enrolled more than 50 patients; (2) the follow-up was more than 12 months; (3) the type of surgery was not restricted; and (4) the patients had first-time invasive breast cancer. The exclusion criteria were as follows: (1) the results were published in a case report or systematic review; (2) no comparison group was used; or (3) the patients had rare types of tumors, such as phyllodes, sarcoma, or lymphoma. The search covered articles published up to 2014 (the progression of study selection is shown in [Fig 1](#pone.0125655.g001){ref-type="fig"}). All of this work was completed independently by two reviewers. If there were different opinions, then a third reviewer was consulted to reach a consensus.

![A flow diagram of the search process.](pone.0125655.g001){#pone.0125655.g001}

Quality assessment {#sec008}
------------------

The quality of the articles was assessed by using the MINORs (methodological index for non-randomized studies) scale, a validated, 12-item tool with a total of 24-points\[[@pone.0125655.ref014]\]. Inter-rater reliability was assessed using Cohen Kappa statistic. The level of agreement between the two reviewers is reported with a Kappa value, the interpretation of Kappa as follows: Kappa \< 0, less than chance agreement; 0.01--0.20, slight agreement; 0.21--0.40, fair agreement; 0.41--0.60, moderate agreement; 0.61--0.80, substantial agreement; 0.81--0.99, almost perfect agreement\[[@pone.0125655.ref015]\].

Data extraction {#sec009}
---------------

The following information was extracted from all of the eligible studies: first author's name and country, year of publication, number of patients enrolled, age, tumor stage, type of reconstruction, type of surgery, follow-up time, recurrence (including local recurrence, locoregional recurrence, and distant recurrence), disease-free survival (DFS) and overall survival (OS).

Statistical analysis {#sec010}
--------------------

For the overall recurrence, DFS, and OS of each study, the relative risk (RR) and its 95% CI were used to estimate the association between the different variants. Between-study heterogeneity of the RRs for the same outcome was tested by determining the Q statistic\[[@pone.0125655.ref016]\]. If *P*\>0.10, indicating that there was no significant heterogeneity between studies, then the fixed-effects model was used to calculate the pooled RRs. If the between-study heterogeneity was significant, then a random-effects model was selected. The I^2^ index can reflect the severity of the heterogeneity. An I^2^ value of less than 25% represents low heterogeneity; 25% to 50%, moderate heterogeneity; and more than 50%, high heterogeneity\[[@pone.0125655.ref017]\].

Publication bias was investigated by constructing a funnel plot, in which the standard error of log (RR) of each study was plotted against its log (RR). If the funnel plot was asymmetric, then Egger's linear regression was used to test for publication bias. The significance of the intercept was determined by the *t* test, as suggested by Egger, and a *P* value less than 0.05 was considered significant\[[@pone.0125655.ref018]\]. To test the reliability of the results of the meta-analysis, we made sensitive analysis by excluding a study and comparing the results with or without this study. All analyses were conducted by using Review Manager 5.1 (The Nordic Cochrane Centre, The Cochrane Collaboration, 2011) and SPSS Statistical software (Version 19, SPSS Inc., IBM). The outcomes of the meta-analysis are presented graphically with Forest plots.

Results {#sec011}
=======

After searching the databases mentioned above, 53 articles received full text review, of which 14 studies met the inclusion criteria. Of these 14 eligible studies, 11 were retrospective cohort studies, including 2 matched-cohort studies, 1 was an historical prospective cohort study, and 2 were prospective cohort studies. The studies included a total of 3641 cases and 9462 controls\[[@pone.0125655.ref019]--[@pone.0125655.ref032]\]. Patients of 4 studies had skin-sparing or nipple-sparing mastectomy and IBR\[[@pone.0125655.ref020],[@pone.0125655.ref023],[@pone.0125655.ref025],[@pone.0125655.ref027]\], while the others had mastectomy associated with IBR\[[@pone.0125655.ref019],[@pone.0125655.ref021]--[@pone.0125655.ref022],[@pone.0125655.ref024],[@pone.0125655.ref026],[@pone.0125655.ref028]--[@pone.0125655.ref032]\]. Most of the control patients underwent mastectomy; only two study enrolled patients underwent breast conservation surgery or nipple-preserving mastectomy into the control group\[[@pone.0125655.ref020],[@pone.0125655.ref026]\]. All studies reported recurrence (including local recurrence, regional recurrence, or distant metastasis), 6 reported DFS, and 8 reported OS. The summary information of the included studies is shown in Tables [1](#pone.0125655.t001){ref-type="table"}, [2](#pone.0125655.t002){ref-type="table"} and [3](#pone.0125655.t003){ref-type="table"}.

10.1371/journal.pone.0125655.t001

###### Demographics of cohort studies included in the meta-analysis.

![](pone.0125655.t001){#pone.0125655.t001g}

  Author(year published)                    Patients/n IBR/Control                          Age, yearsIBR/Control                             Region of study   Follow-up/mIBR/Control   Adjuvant treatments   Mastectomy type   Reconstruction type                   Study Design
  ----------------------------------------- ----------------------------------------------- ------------------------------------------------- ----------------- ------------------------ --------------------- ----------------- ------------------------------------- --------------------------------------
  **Noguchi\[[@pone.0125655.ref019]\]**     83/153                                          82/47.7[^a^](#t001fn001){ref-type="table-fn"}     Japan             41/58                    CT                    MT                LDM, TRAM,                            Retrospective cohort study
  **(1992)**                                Implant                                                                                                                                                                                                                    
  **Yoshimura\[[@pone.0125655.ref020]\]**   122/92                                          44/50[^b^](#t001fn002){ref-type="table-fn"}       Japan             78/55                    CT                    NMT               NMT +Implant                          Retrospective cohort study
  **(1996)**                                                                                                                                                                                                                                                           
  **Murphy\[[@pone.0125655.ref021]\]**      158/1262                                        48/66[^b^](#t001fn002){ref-type="table-fn"}       USA               75/75                    NA                    MT                Implant, TRAM,                        Retrospective cohort study
  **(2002)**                                LD+implant                                                                                                                                                                                                                 
  **Petit\[[@pone.0125655.ref022]\]**       518/159                                         69.3/22[^a^](#t001fn001){ref-type="table-fn"}     Italy             70/71                    CT, HT                MT                Implant, TRAM,                        Retrospective cohort study
  **(2008)**                                LD+implant                                                                                                                                                                                                                 
  **Ueda\[[@pone.0125655.ref023]\]**        74/178                                          45.7/55[^c^](#t001fn003){ref-type="table-fn"}     Japan             50/54                    CT, HT, RT            MT                SMIBR+TRAM,                           Prospective cohort study
  **(2008)**                                LD, Implant, DIEP                                                                                                                                                                                                          
  **McCarthy\[[@pone.0125655.ref024]\]**    309/309                                         46.8/50.8[^c^](#t001fn003){ref-type="table-fn"}   USA               68.4/68.4                CT, HT, RT            MT                Implant, tissue,                      Retrospective cohort study (matched)
  **(2008)**                                expander                                                                                                                                                                                                                   
  **Gerber\[[@pone.0125655.ref025]\]**      108/130                                         47/58[^b^](#t001fn002){ref-type="table-fn"}       Germany           101/101                  CT, RT                MT                SMIBR+LD,                             Historical prospective cohort study
  **(2009)**                                implant                                                                                                                                                                                                                    
  **Min \[[@pone.0125655.ref026]\]**        120/1699                                        40.7/47.6[^b^](#t001fn002){ref-type="table-fn"}   Korea             42.1/39.2                CT, RT                BCS               LD                                    Retrospective cohort study
  **(2010)**                                                                                                                                                                                                                                                           
  **Lim\[[@pone.0125655.ref027]\]**         87/810                                          38.4/47.4[^b^](#t001fn002){ref-type="table-fn"}   Korea             62.5/65                  CT, HT, RT            MT                SMIBR+TRAM,                           Retrospective cohort study (matched)
  **(2010)**                                LD, implant                                                                                                                                                                                                                
  **Noguchi\[[@pone.0125655.ref019]\]**     83/153                                          82/47.7[^a^](#t001fn001){ref-type="table-fn"}     Japan             41/58                    CT                    MT                LDM, TRAM,                            Retrospective cohort study
  **(1992)**                                Implant                                                                                                                                                                                                                    
  **Yoshimura\[[@pone.0125655.ref020]\]**   122/92                                          44/50[^b^](#t001fn002){ref-type="table-fn"}       Japan             78/55                    CT                    NMT               NMT +Implant                          Retrospective cohort study
  **(1996)**                                                                                                                                                                                                                                                           
  **Murphy\[[@pone.0125655.ref021]\]**      158/1262                                        48/66[^b^](#t001fn002){ref-type="table-fn"}       USA               75/75                    NA                    MT                Implant, TRAM,                        Retrospective cohort study
  **(2002)**                                LD+implant                                                                                                                                                                                                                 
  **Petit\[[@pone.0125655.ref022]\]**       518/159                                         69.3/22[^a^](#t001fn001){ref-type="table-fn"}     Italy             70/71                    CT, HT                MT                Implant, TRAM,                        Retrospective cohort study
  **(2008)**                                LD+implant                                                                                                                                                                                                                 
  **Ueda\[[@pone.0125655.ref023]\]**        74/178                                          45.7/55[^c^](#t001fn003){ref-type="table-fn"}     Japan             50/54                    CT, HT, RT            MT                SMIBR+TRAM,                           Prospective cohort study
  **(2008)**                                LD, Implant, DIEP                                                                                                                                                                                                          
  **McCarthy\[[@pone.0125655.ref024]\]**    309/309                                         46.8/50.8[^c^](#t001fn003){ref-type="table-fn"}   USA               68.4/68.4                CT, HT, RT            MT                Implant, tissue,                      Retrospective cohort study (matched)
  **(2008)**                                expander                                                                                                                                                                                                                   
  **Gerber\[[@pone.0125655.ref025]\]**      108/130                                         47/58[^b^](#t001fn002){ref-type="table-fn"}       Germany           101/101                  CT, RT                MT                SMIBR+LD,                             Historical prospective cohort study
  **(2009)**                                implant                                                                                                                                                                                                                    
  **Min \[[@pone.0125655.ref026]\]**        120/1699                                        40.7/47.6[^b^](#t001fn002){ref-type="table-fn"}   Korea             42.1/39.2                CT, RT                BCS               LD                                    Retrospective cohort study
  **(2010)**                                                                                                                                                                                                                                                           
  **Lim\[[@pone.0125655.ref027]\]**         87/810                                          38.4/47.4[^b^](#t001fn002){ref-type="table-fn"}   Korea             62.5/65                  CT, HT, RT            MT                SMIBR+TRAM,                           Retrospective cohort study (matched)
  **(2010)**                                LD, implant                                                                                                                                                                                                                
  **Eriksen\[[@pone.0125655.ref028]\]**     300/300                                         48/48[^c^](#t001fn003){ref-type="table-fn"}       Sweden            144/138                  CT, HT, RT            MT                implant                               Retrospective cohort study
  **(2011)**                                                                                                                                                                                                                                                           
  **Nedumpara\[[@pone.0125655.ref029]\]**   135/452                                         47/59[^c^](#t001fn003){ref-type="table-fn"}       England           55/55                    CT, HT, RT            MT                LD, implant                           Retrospective cohort study
  **(2011)**                                                                                                                                                                                                                                                           
  **Reddy\[[@pone.0125655.ref030]\]**       494/427[^c^](#t001fn003){ref-type="table-fn"}   47.8/56.4[^c^](#t001fn003){ref-type="table-fn"}   USA               54/54                    CT, HT, RT            MT                DIEP, LD, TRAM, SGAP, SIEA, implant   Retrospective cohort study
  **(2011)**                                                                                                                                                                                                                                                           
  **Lee\[[@pone.0125655.ref031]\]**         1000/3183                                       42.2/47.9[^b^](#t001fn002){ref-type="table-fn"}   Korea             56.4/60                  NA                    MT                TRAM                                  Retrospective cohort study
  **(2012)**                                                                                                                                                                                                                                                           
  **Ota\[[@pone.0125655.ref032]\]**         133/308                                         46/58[^c^](#t001fn003){ref-type="table-fn"}       Japan             47/44                    CT, HT, RT            MT                TE                                    Prospective cohort study
  **(2014)**                                                                                                                                                                                                                                                           

^a^ Percentage of patients younger than 50 years

^b^ mean age

^c^ median age.

N:number, m:months, BCS, breast conserving surgery, CT: chemotherapy, DIEP: deep inferior epigastric perforator, HT: hormonal therapy, IBR, immediate breast reconstruction, LD: latissimus dorsi, MT: mastectomy, RT: radiation therapy, S-GAP: superior Gluteus artery perforator, SIEA: superficial inferior epigastric artery flap, SMIBR: skin-sparing/nipple-sparing mastectomy and immediate breast reconstruction, TE: tissue expander, TRAM: transverse rectus abdominis musculocutaneous; NMT: nipple-preserving mastectomy

10.1371/journal.pone.0125655.t002

###### Outcome of the cohort studies included in the meta-analysis.

![](pone.0125655.t002){#pone.0125655.t002g}

  Author                                    AJCC tumor stage   Recurrence        DFS           OS
  ----------------------------------------- ------------------ ----------------- ------------- -------------
  **Noguchi\[[@pone.0125655.ref019]\]**     0-III              IBR:3/83          IBR:75/83     IBR:76/83
  Control:7/153                             Control:132/153    Control:140/153                 
  **Yoshimura\[[@pone.0125655.ref020]\]**   I-II               IBR:14/122        IBR:108/122   IBR:116/122
  Control:9/92                              Control:81/92      Control:89/92                   
  **Murphy\[[@pone.0125655.ref021]\]**      0-IV               IBR:2/158         NA            NA
  Control:9/1262                                                                               
  **Petit\[[@pone.0125655.ref022]\]**       I-III              IBR:110/518       IBR:392/518   IBR:464/518
  Control:43/159                            Control:110/159    Control:133/159                 
  **Ueda\[[@pone.0125655.ref023]\]**        0-III              IBR:8/74          IBR:67/74     NA
  Control:19/178                            Control:160/178                                    
  **McCarthy\[[@pone.0125655.ref024]\]**    I-III              IBR:59/309        NA            NA
  Control:74/309                                                                               
  **Gerber\[[@pone.0125655.ref025]\]**      0-III              IBR:12/108        NA            IBR:83/108
  Control:15/130                            Control:100/130                                    
  **Min\[[@pone.0125655.ref026]\]**         0-IV               IBR:9/120         NA            NA
  Control:133/1699                                                                             
  **Lim\[[@pone.0125655.ref027]\]**         IIB-III            IBR:4/87          IBR:61/87     IBR:69/87
  Control:20/810                            Control:547/810    Control:607/810                 
  **Eriksen\[[@pone.0125655.ref028]\]**     I-III              IBR:85/300        NA            IBR:249/300
  Control:98/300                            Control:231/300                                    
  **Nedumpara\[[@pone.0125655.ref029]\]**   NA                 IBR:12/135        NA            IBR:108/135
  Control:38/452                            Control:360/452                                    
  **Reddy\[[@pone.0125655.ref030]\]**       0-III              IBR:11/494        NA            NA
  Control:17/427                                                                               
  **Lee\[[@pone.0125655.ref031]\]**         0-III              IBR:18/1000       NA            NA
  Control:38/3183                                                                              
  **Ota\[[@pone.0125655.ref032]\]**         NA                 IBR:15/133        IBR:118/133   IBR:125/133
  Control:35/308                            Control:271/308    Control:290/308                 

AJCC: American Joint Committee on Cancer, DFS: disease-free survival, IBR, immediate breast reconstruction, NA: not available, OS: overall survival

10.1371/journal.pone.0125655.t003

###### Clinical stage of the studies included in the meta-analysis.

![](pone.0125655.t003){#pone.0125655.t003g}

  Stage[^&^](#t003fn001){ref-type="table-fn"}                                      0-I IBR/Control   II IBR/Control   III IBR/Control   IV IBR/Control   Other IBR/Control
  -------------------------------------------------------------------------------- ----------------- ---------------- ----------------- ---------------- -------------------
  **Noguchi\[[@pone.0125655.ref019]\]**                                            25.3/30           57.8/48.4        16.9/21.6                          
  **Yoshimura\[[@pone.0125655.ref020]\]**                                          82.1/79.3         17.9/20.7                                           
  **Murphy\[[@pone.0125655.ref021]\]**                                             54.4/44.2         30.4/31          2.5/12.8          1.3/4.1          11.4/7.8
  **Petit\[[@pone.0125655.ref022]\]** [\*](#t003fn002){ref-type="table-fn"}        14.9/8.2          44/41.5          36.9/44                            
  **Ueda\[[@pone.0125655.ref023]\]** [^**\#**^](#t003fn003){ref-type="table-fn"}   55.4/40           44.6/57.8        0/2.2                              
  **McCarthy\[[@pone.0125655.ref024]\]**                                           31.7/31.7         53.1/53.1        15.2/15.2                          
  **Gerber\[[@pone.0125655.ref025]\]**                                             20.4/27           74.1/68          5.5/5                              
  **Min\[[@pone.0125655.ref026]\]**                                                56.7/44           25.8/40.7        10.8/11.5         0/0.3            
  **Lim\[[@pone.0125655.ref027]\]**                                                                  9.2/6.7          90.8/93.3                          
  **Eriksen\[[@pone.0125655.ref028]\]**                                            NA                                                                    
  **Nedumpara\[[@pone.0125655.ref029]\]**                                          NA                                                                    
  **Reddy\[[@pone.0125655.ref030]\]**                                              61.1/39.3         23.1/38          8.7/18.7                           
  **Lee\[[@pone.0125655.ref031]\]**                                                53.7/28.1         37.1/46.3        7.7/15.1                           
  **Ota\[[@pone.0125655.ref032]\]**                                                NA                                                                    

^&^ The value is percentage

\* Grading

^**\#**^ Tumor stage

NA not available.

All 14 studies were independently assessed by 2 of the authors using the MINORs scale. The scores of these studies ranged from 16 to 21 points. The inter-rater reliability was 0.745, which signifies a substantial level of agreement. A funnel plot of the studies is symmetric, which demonstrates that there is no apparent publication bias ([Fig 2](#pone.0125655.g002){ref-type="fig"}).

![A funnel plot of the 14 included studies.](pone.0125655.g002){#pone.0125655.g002}

First, overall recurrence was examined across the 14 studies; no significant heterogeneity was found (Q statistic: *P* = 0.65; I^2^ = 0%). The pooled RR for overall recurrence was 0.89 (95%CI: 0.75, 1.04). As shown in [Fig 3](#pone.0125655.g003){ref-type="fig"}, the results indicate that there was no significant difference in cancer recurrence between patients who underwent IBR and the control patients (*P* = 0.14).

![A Forest plot of the pooled RR of recurrence for the IBR and Control groups.](pone.0125655.g003){#pone.0125655.g003}

DFS was reported by 6 studies that enrolled a total of 1017 cases and 1700 controls. The heterogeneity among the studies was not significant (Q statistic: *P* = 0.81; I^2^ = 0%). The pooled RR was 1.04 (95%CI: 0.99, 1.08), indicating that IBR was not associated with an increased risk in patients' DFS (*P* = 0.10; [Fig 4](#pone.0125655.g004){ref-type="fig"}).

![A Forest plot of the pooled RR of DFS for the IBR and Control groups.](pone.0125655.g004){#pone.0125655.g004}

OS was reported by 8 studies that enrolled a total of 1486 cases and 2404 controls. There was no significant heterogeneity among the studies (Q statistic: P = 0.34; I^2^ = 12%). The pooled RR, which was 1.02 (95%CI: 0.99, 1.05; *P* = 0.24), demonstrates that IBR had no impairment on prognosis of patients with invasive breast cancer ([Fig 5](#pone.0125655.g005){ref-type="fig"})

![A Forest plot of the pooled RR of OS for the IBR and Control group](pone.0125655.g005){#pone.0125655.g005}

In sensitive analysis, the results for recurrence, DFS, and OS were consistent in each single exclusion analysis ([Table 4](#pone.0125655.t004){ref-type="table"}).

10.1371/journal.pone.0125655.t004

###### Sensitive analysis by excluding each single study.

![](pone.0125655.t004){#pone.0125655.t004g}

  Results Excluded study                    Recurrence RR(95%CI) and P value   DFS RR(95%CI) and P value    OS RR(95%CI) and P value
  ----------------------------------------- ---------------------------------- ---------------------------- ----------------------------
  **Noguchi\[[@pone.0125655.ref019]\]**     0.90(0.79, 1.03), P = 0.11         0.99(0.93, 1.05),P = 0.71    1.02(0.99, 1.06), P = 0.22
  **Yoshimura\[[@pone.0125655.ref020]\]**   0.89(0.78, 1.02), P = 0.09         1.00(0.94, 1.05), P = 0.91   1.03(0.99, 1.06), P = 0.10
  **Murphy\[[@pone.0125655.ref021]\]**      0.89(0.78, 1.02), P = 0.09                                      
  **Petit\[[@pone.0125655.ref022]\]**       0.93(0.80, 1.07), P = 0.30         1.02(0.98, 1.07), P = 0.39   1.01(0.98, 1.04), P = 0.58
  **Ueda\[[@pone.0125655.ref023]\]**        0.90(0.78, 1.02), P = 0.10         1.00(0.94, 1.05), P = 0.90   
  **McCarthy\[[@pone.0125655.ref024]\]**    0.92(0.80, 1.07), P = 0.28                                      
  **Gerber\[[@pone.0125655.ref025]\]**      0.90(0.78,1.02), P = 0.11                                       1.02(0.99, 1.05), P = 0.24
  **Min\[[@pone.0125655.ref026]\]**         0.90(0.78, 1.02), P = 0.11                                      
  **Lim\[[@pone.0125655.ref027]\]**         0.89(0.78,1.01), P = 0.08          0.99(0.94, 1.04), P = 0.69   1.02(0.98, 1.05), P = 0.34
  **Eriksen\[[@pone.0125655.ref028]\]**     0.91(0.78,1.06), P = 0.24                                       1.01(0.98, 1.04), P = 0.56
  **Nedumpara\[[@pone.0125655.ref029]\]**   0.89(0.78, 1.02), P = 0.09                                      1.02(0.99, 1.06), P = 0.24
  **Reddy\[[@pone.0125655.ref030]\]**       0.91(0.80, 1.04), P = 0.17                                      
  **Lee\[[@pone.0125655.ref031]\]**         0.87(0.76,1.01), P = 0.06                                       
  **Ota\[[@pone.0125655.ref032]\]**         0.89(0.78, 1.02), P = 0.10         0.99(0.93, 1.06), P = 0.86   1.02(0.99, 1.06), P = 0.17

Discussion {#sec012}
==========

Mastectomy remains the primary treatment for patients with breast cancer. Studies have shown that in recent years, the proportion of patients who choose mastectomy is increasing compared to breast-conserving surgery, and patients are more likely to be advised to select mastectomy for better control of local recurrence\[[@pone.0125655.ref033],[@pone.0125655.ref034]\]. IBR after surgery can benefit patients, and an increasing number of patients now opt to undergo this procedure. However, its application is still limited. There are several possible reasons for this limitation, such as concerns about how the surgery will affect future treatments, the fact that breast reconstruction is not a high priority, or lack of knowledge about this type of surgery.

Our meta-analysis shows that IBR is not associated with an increased risk of recurrence (*P* = 0.14). There was no significant publication bias among the included studies, so bias had little effect on the pooled result. A meta-analysis by Gieni et al. (2012) examined the local recurrence of breast cancer among patients who received IBR. The pooled result of this analysis showed no evidence for an association between increased frequency of local recurrence and IBR after mastectomy compared with mastectomy alone\[[@pone.0125655.ref035]\]. These findings are similar to our own in regards to the rate of recurrence.

Meanwhile, there were no significant differences in DFS or OS between the patients who underwent IBR and the control patients, IBR did not have adverse effect on the prognosis of patients with breast cancer. Some studies even have a result that IBR was associated with an improved prognosis\[[@pone.0125655.ref036]--[@pone.0125655.ref038]\]. Bezuhly et al used data from the SEER registries to study breast cancer-specific survival in women who underwent unilateral mastectomy with or without IBR. The authors observed improved survival among patients in the IBR group compared with that of patients who underwent mastectomy alone (hazard ratio \[HR\] = 0.74; 95%CI, 0.68, 0.80)\[[@pone.0125655.ref036]\]. Studies by Agarwal S and Agarwal J\[[@pone.0125655.ref037],[@pone.0125655.ref038]\], one of which was a multivariate analysis that controlled for the demographic and oncologic covariates of 51702 patients\[[@pone.0125655.ref037]\], showed that patients treated with mastectomy and reconstruction had a significantly lower risk of death than did patients treated with mastectomy only (HR: 0.62, *P*\<0.001 and 0.73, *P*\<0.0001). The underlying reasons for this phenomenon may be due to direct physiological or immunological effects\[[@pone.0125655.ref039]\]. However, another possibility is that patients who receive IBR may be more invested in their care. Therefore, these patients may be more likely to pursue oncological or general healthcare, and this behavior may translate to higher survival\[[@pone.0125655.ref037]\]. Morrow et al have shown that patients with a family income of \$40 000 or more were more likely to undergo reconstruction than were patients with an income of less than \$40 000\[[@pone.0125655.ref040]\]. Women with higher incomes may experience improved survival after breast cancer because of better access to cancer care and treatment.

Our study is a systematic review of the available literature that examined overall recurrence/DFS/OS in patients undergoing mastectomy with or without IBR. There are limitations inherent in retrospective reviews, including bias that occurs when designing the review, and this may be a limitation of our study. We limited our search to manuscripts published in English; thus, we may have missed some studies published in other languages. Similarly, the key words that we used may have affected the search. Although overall recurrence included both local and systemic recurrence, not all of the published studies reported data for this outcome. In addition, DFS and OS were also not included in all studies; this is a third limitation of our meta-analysis. We searched for studies with inclusive criteria; such a restriction may have an effect on the final results by excluding studies that had fewer patients, shorter follow-up time or lacked a comparison group. These restrictions may also have introduced a limitation to our study. Finally, some confounding patient factors that affect prognosis, such as tumor stage, patient age, and patient social economic status cannot be controlled in retrospective studies and may also have effect on the results.

Meta-analysis is usually applied to observational studies. One report indicates that the tendency towards publication bias is greater with observational studies than with randomized clinical trials\[[@pone.0125655.ref041]\]. Publication bias should always be evaluated to assess the credibility of any meta-analysis. Other studies have found that a smaller sample size or negative results in a published study are more likely to lead to publication bias and that the selective publication of meaningful or important discoveries will affect the reliability of the pooled results of a meta-analysis\[[@pone.0125655.ref042],[@pone.0125655.ref043]\]. For this study, we evaluated publication bias by constructing a funnel plot, which demonstrated that there was no apparent publication bias in our study. To test the reliability of these meta-analysis results, we need to do a more sensitive analysis. There are different methods to accomplish this task. We used the method of excluding each single study in series, and we found that the results for recurrence, DFS, and OS were consistent in each single exclusion analysis, Thus, we are confident that the results of this study are reliable.

In this meta-analysis, we found no evidence to support the hypothesis that IBR increases the risk of postoperative recurrence and death. Therefore, this procedure can be a safe and rational choice.

Conclusion {#sec013}
==========

We examined the effects of immediate breast reconstruction on patient prognosis by conducting a meta-analysis. Our results suggest that there are no significant differences in overall recurrence, DFS, or OS between patients who have undergone IBR after mastectomy and those who were treated with mastectomy only. More high-quality evidence is needed in this field to allow clinicians to make better choices regarding treatment regimens.

Supporting Information {#sec014}
======================

###### PRISMA checklist.

(DOC)

###### 

Click here for additional data file.

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.

[^2]: Conceived and designed the experiments: XY. Performed the experiments: XY CFZ. Analyzed the data: XY CFZ. Contributed reagents/materials/analysis tools: XY CFZ. Wrote the paper: XY CFZ YG.
